Kim Schenk

Vice President

Ms. Schenk has over twenty years of experience in providing damages analysis and expert witness testimony in patent, trademark, trade secret, and copyright litigation engagements.

Her experience includes quantifying lost profits, reasonable royalties, price erosion, and defendants’ profits across a wide variety of industries and products, including medical devices, pharmaceuticals, software, mobile and web platforms, digital imaging, and consumer products. She has also evaluated commercial success, irreparable harm, and domestic industry. Ms. Schenk has testified as an expert witness in cases in Federal and State Court, including more than a dozen intellectual property trials.

In addition to her experience in intellectual property matters, Ms. Schenk has performed damages assessments for a variety of other types of business disputes, including false advertising matters, breach of contract litigation, and general commercial disputes. She has been involved in valuations of privately held businesses, patents and patent portfolios, trademarks, non-competition agreements, and other intangible assets. She also managed several large business valuation projects in the context of estate tax and transfer pricing disputes.

Ms. Schenk has been included in the IAM Patent 1000 rankings each year since 2019, the IAM Strategy 300 in 2023, and Who’s Who Legal’s Recommended IP Experts in 2023.

Selected engagements

  • 01
    Trial testimony on patent damages in the U.S. Court of Federal Claims
    CRA’s Intellectual Property experts were retained to assess the amount of reasonable and entire compensation for the Transportation Security Administration’s...
    View engagement
  • 02
    Jury awards $3.2 million in false advertising matter based on CRA expert’s testimony
    Following a trial in Green Bay, Wisconsin, a jury awarded CRA client BenShot LLC damages totaling $3.2 million, including $2.8 million in lost profits damages...
    View engagement
  • 03
    Federal Circuit affirms $107 million judgment in patent case based on expert’s testimony
    The ‘991 patent covers a drug formulation that uses magnesium stearate combined with an active ingredient to form composite active particles that improve the...
    View engagement

Credentials